Therapy Areas: Vaccines
YS Biopharma's YS-HBV-002 receives Philippine clinical trial approval
19 April 2024 - YS Biopharma Co., Ltd. (Nasdaq: YS), a China-based global biopharmaceutical company, announced on Thursday that it has received clinical trial approval from the Philippine Food and Dru...
Anixa Biosciences adds Dr Sanjay Juneja to Cancer Business Advisory Board
19 April 2024 - Anixa Biosciences, Inc. (NASDAQ: ANIX), a California-based clinical-stage biotechnology company, announced on Thursday that it has added Sanjay Juneja, MD to its Cancer Business Adviso...
Circio ends TG01 cancer vaccine licence deal with IOVaxis in China
17 April 2024 - Circio Holding ASA (OSE:CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy and cancer vaccines, revealed on Wednesday that it has...
GSK releases decade-long data on Shingrix efficacy
17 April 2024 - Biopharmaceutical company GSK plc (LSE/NYSE:GSK) on Wednesday announced positive data from the ZOSTER-049 long-term follow-up phase III trial, spanning up to approximately 11 years pos...
GSK's meningitis vaccine candidate accepted for FDA review
16 April 2024 - Biopharmaceutical company GSK plc (LSE/NYSE: GSK) announced on Tuesday that the US FDA has accepted its 5-in-1 meningococcal ABCWY vaccine candidate for regulatory review. The Prescrip...
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
12 April 2024 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the company), a late-stage biopharmaceutical company, announced on Thursday that it has received orphan drug designation for the active ing...